New pharmacological strategies for the treatment of non-infectious Uveitis. A Minireview
Author
dc.contributor.author
Valenzuela Bassi, Rodrigo
Author
dc.contributor.author
Flores, Iván Godoy
Author
dc.contributor.author
Urrutia Ramírez, María
Author
dc.contributor.author
Fuentes, Francisca
Author
dc.contributor.author
Sabat Opazo, Pablo E.
Author
dc.contributor.author
Llanos, Carolina
Author
dc.contributor.author
Cuitiño Tride, Loreto
Author
dc.contributor.author
Urzúa Salinas, Cristhian A.
Admission date
dc.date.accessioned
2020-07-15T21:12:11Z
Available date
dc.date.available
2020-07-15T21:12:11Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Front Pharmacol. 2020; 11: 655.
es_ES
Identifier
dc.identifier.other
10.3389/fphar.2020.00655
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/176006
Abstract
dc.description.abstract
Non-infectious uveitis (NIU) is a group of disorders characterized by intraocular inflammation at different levels of the eye. NIU is a leading cause of irreversible blindness in working-age population in the developed world. The goal of uveitis treatment is to control inflammation, prevent recurrences, and preserve vision, as well as minimize the adverse effects of medications. Currently, the standard of care for NIU includes the administration of corticosteroids (CS) as first-line agents, but in some cases a more aggressive therapy is required. This includes synthetic immunosuppressants, such as antimetabolites (methotrexate, mycophenolate mofetil, and azathioprine), calcineurinic inhibitors (cyclosporine, tacrolimus), and alkylating agents (cyclophosphamide, chlorambucil). In those patients who become intolerant or refractory to CS and conventional immunosuppressive treatment, biologic agents have arisen as an effective therapy. Among the most evaluated treatments, TNF-alpha inhibitors, IL blockers, and anti-CD20 therapy have emerged. In this regard, anti-TNF agents (infliximab and adalimumab) have shown the strongest results in terms of favorable outcomes. In this review, we discuss latest evidence concerning to the effectiveness of biologic therapy, and present new therapeutic approaches directed against immune components as potential novel therapies for NIU.
es_ES
Patrocinador
dc.description.sponsorship
Comisión Nacional de Investigación Cientifica y Tecnológica (CONICYT)
CONICYT FONDEF
IT17I0087
National Agency for Research and Development (ANID) grant Fondecyt de Iniciacion en Investigacion
11191215